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than do older individuals. The factors explaining these differences remain unclear. The objective
of this article was to explore factors associated with age-related differences in HRQL in COPD.
METHODS: Cross-sectional analysis of participants with COPD, any Global Initiative for
Chronic Obstructive Lung Disease grade of airflow limitation, and $ 50 years old in two
cohorts: the Genetic Epidemiology of COPD (COPDGene) study and the Subpopulations and
Intermediate Outcome Measures in COPD Study (SPIROMICS). We compared St. George’s
Respiratory Questionnaire (SGRQ) scores by age group: middle-aged (age, 50-64) vs older
(age, 65-80) adults. We used multivariate linear modeling to test associations of age with
HRQL, adjusting for demographic and clinical characteristics and comorbidities.
RESULTS: Among 4,097 participants in the COPDGene study (2,170 middle-aged and
1,927 older adults) SGRQ total scores were higher (worse) among middle-aged (mean differ-
ence, 4.2 points; 95% CI, 5.7 to 2.6; P < .001) than older adults. Age had a statistically
significant interaction with dyspnea (P < .001). Greater dyspnea severity (modified Medical
Research Council$ 2, compared with 0-1) had a stronger association with SGRQ score among
middle-aged (b, 24.6; 95% CI, 23.2-25.9) than older-adult (b, 21.0; 95% CI, 19.6-22.3) partic-
ipants. In analyses using SGRQ as outcome in 1,522 participants in SPIROMICS (598 middle-
aged and 924 older adults), we found similar associations, confirming that for the same severity
of dyspnea there is a stronger association with HRQL among younger individuals.
CONCLUSIONS: Age-related differences in HRQL may be explained by a higher impact of
dyspnea among younger subjects with COPD.
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The experience of living with a chronic disease, such
as COPD, not only affects physiological domains
but also impacts and requires significant adjustments
in other physical, mental, and emotional domains of
life. For this reason, the overall impact of chronic
diseases is best described using measures of health
status or health-related quality of life (HRQL),
which provide information beyond organ-centered
physiological descriptors.1,2 Studies of HRQL in
COPD show that, independent of lung function,
younger adults tend to report worse scores than do
older adults, suggesting a pattern of more negative
perception of health among younger subjects.3,4 Little
is known about the reasons for these differencesDrs Cigolle and Han contributed equally to this manuscript.
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COPD.
In this article, using data from two contemporary,
well-characterized COPD cohorts with a wide spectrum
of disease severities, we evaluated both the presence of
age-related differences in HRQL and whether factors
influencing this measure of disease impact differ across
age groups. We hypothesized that age-related differences
in HRQL may be explained by different levels of
tolerance of respiratory symptoms. Specifically, we
hypothesized that dyspnea has a stronger impact on
HRQL among middle-aged than older adults with
COPD.Materials and Methods
Design and Study Participants
This study is a cross-sectional analysis of data from participants
with COPD in two cohorts: the Genetic Epidemiology of COPD
(COPDGene) study5 and the Subpopulations and Intermediate
Outcome Measures in COPD Study (SPIROMICS).6 The protocols
for SPIROMICS and the COPDGene study were approved by
the institutional review boards of all participating institutions.
COPDGene data were used to examine the main hypothesis, and
the robustness of the findings was tested in participants in
SPIROMICS. For this analysis, we selected participants with
COPD, both former and current smokers, who met Global
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
for COPD, were $ 50 years old, and had any GOLD grade of
airflow limitation. For comparison, participants were further
classified as middle-aged (age, 50-64 years) or older (age, 65-80years) adults. An expanded version of the methods is available as a
supplementary e-Appendix 1.
Data Collection
Demographic data, smoking history, symptoms, exacerbation
history, comorbidities, and medical history were collected using
self-administered questionnaires.5,6 Dyspnea was assessed using the
modified Medical Research Council (mMRC) scale,7 which was
further categorized using the cut points suggested by GOLD
recommendations8 (0-1 vs 2-4). Frequent exacerbation was defined
as $ 2 per year.9,10 Baseline St. George’s Respiratory
Questionnaire (SGRQ) total score was the main outcome measure
of this study.11,12
Statistical Analysis
Respondents were analyzed according to their age at enrollment. We
used descriptive statistics for demographic and clinical variables
(means and proportions) for each cohort. Multivariate linear models
were used to identify the effect of age group (predictor of interest)
on SGRQ total score, while controlling for covariates relevant
to theoretical models of HRQL (demographics, smoking and
exacerbation history, lung function, respiratory symptoms, and
comorbidities). We included interaction terms between age
and dyspnea score on the basis of our a priori hypothesis; for
significant interactions, we calculated the effect of each variable by
age group. To test the robustness of our results, we replicated the
initial analyses in the COPDGene cohort (discovery cohort) by using
the SPIROMICS cohort (validation cohort) for the shared outcome
(SGRQ total score). All analyses were performed using Stata
version12 software (StataCorp).
Results
The two cohorts were similar in overall composition
(Table 1), including a substantial proportion of
women (range, 41.0%-45.0%), current smokers (range,
21.5%-57.3%), and individuals with chronic bronchitis
(range, 18.5%-30.6%). Differences between the cohorts
included a greater proportion of African Americans,
higher cumulative smoking history, and more severe
dyspnea in the COPDGene cohort. Almost all[ 1 4 9 # 4 CHES T A P R I L 2 0 1 6 ]
comorbidities were more frequent among older adult
participants, with the exception of asthma. A similar
pattern of demographic and clinical differences was
found among participants in SPIROMICS (Table 1).
Additionally, among participants in SPIROMICS,TABLE 1 ] General Characteristics of Participants With COP
80 Years
Characteristics
CO
Middle-aged
Adults
(n ¼ 2,170
Sociodemographic characteristics
Age, mean (SD), y 58.3 (4.2)
Female, % 45.0
African American, % 28.3
Current smoker, % 57.3
Pack-y smoked, mean (SD) 49.1 (24.5
BMI $ 30, % 31.2
BMI, mean (SD) 27.9 (6.2)
Time with COPD diagnosis, in y, mean (SD) 7.6 (7.3)
Respiratory status
FEV1 % predicted, mean (SD) 58.2 (22.9
mMRC score, mean (SD) 1.9 (1.5)
mMRC dyspnea score $ 2, % 59.8
GOLD III-IV, % 37.8
Chronic bronchitis, % 29.1
Six-minute walking distance, in m, mean (SD) 385 (126)
Exacerbation per y, mean (SD) 0.7 (1.2)
Severe exacerbations prior y, mean (SD) 0.2 (0.4)
Frequent exacerbations ($ 2/y), % 17.3
Comorbidities, %
Asthma 24.3
Coronary artery disease 5.8
Myocardial infarction 6.9
Peripheral vascular disease 2.3
Stroke 3.2
Congestive heart failure 3.9
Diabetes mellitus 11.0
Gastroesophageal reflux disease 28.6
Musculoskeletal disease 33.1
Anxiety or depression .
HRQL, SGRQ score, mean (SD)
Total 38.9 (23.7
Symptoms 45.8 (26.3
Activity 52.5 (29.7
Impact 29.0 (22.9
Data are presented as mean (SD) or percentage. COPDGene ¼ Genetic Ep
Lung Disease; HRQL ¼ health-related quality of life; mMRC ¼ modified Med
SPIROMICS ¼ Subpopulations and Intermediate Outcome Measures in COPD S
journal.publications.chestnet.organxiety and depression were more common in the
middle-aged adults (data on these conditions were
not collected by the COPDGene study). Older adults
in both cohorts reported better HRQL (lower SGRQ
scores) (Fig 1).D in the COPDGene Study and SPIROMICS, Ages 50 to
PDGene Study SPIROMICS
)
Older Adults
(n ¼ 1,927)
Middle-aged
Adults
(n ¼ 598)
Older Adults
(n ¼ 924)
71.0 (4.0) 58.4 (4.2) 70.8 (4.1)
42.8 44.3 41.0
12.3 22.6 8.4
21.5 46.0 22.5
) 57.2 (29.9) 48.2 (20.5) 56.5 (27.1)
31.3 30.9 30.4
27.8 (5.8) 27.1 (5.5) 27.5 (5.1)
9.9 (9.0) 7.4 (6.3) 10.4 (8.6)
) 54.9 (22.5) 54.4 (22.7) 62.3 (22.1)
1.9 (1.4) 1.5 (1.1) 1.1 (1.0)
58.1 43.1 26.3
44.2 44.0 31.6
21.9 30.6 18.5
359 (122) 399 (138) 389 (123)
0.6 (1.1) 0.8 (1.2) 0.4 (0.8)
0.2 (0.3) 0.4 (0.8) 0.1 (0.5)
13.8 19.9 9.4
19.3 30.4 20.1
13.4 6.7 13.2
9.5 5.7 8.7
4.6 6.9 8.9
4.0 4.5 4.4
5.5 1.8 4.0
14.6 12.2 14.7
31.7 29.1 31.3
44.9 58.0 65.7
. 37.8 28.1
) 34.6 (21.3) 44.7 (19.5) 32.8 (17.4)
) 38.4 (24.2) 60.2 (22.8) 45.8 (22.8)
) 51.3 (28.7) 58.1 (24.9) 46.6 (23.4)
) 24.0 (19.8) 31.7 (19.7) 20.5 (16.3)
idemiology of COPD; GOLD ¼ Global Initiative for Chronic Obstructive
ical Research Council; SGRQ ¼ St. George’s Respiratory Questionnaire;
tudy.
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Figure 1 – SGRQ total score by age group in each cohort. All differences between middle-aged and older adult groups, in each cohort, are
significant at P < .05. The box represents the interquartile range and the central line the median. COPDGene ¼ Genetic Epidemiology of COPD;
SGRQ ¼ St. George’s Respiratory Questionnaire; SPIROMICS ¼ Subpopulations and Intermediate Outcome Measures in COPD Study.Linear models of HRQL demonstrated a significant
association between age and SGRQ. Analyses of data
from participants in the COPDGene study (Table 2)
showed that being older (vs middle-aged) was associated
with a lower SGRQ total score (better HRQL; b, 3.0;
95% CI, 3.9 to 2.0). As predicted by theoretical
models,13 demographic (African American race),
smoking status, and respiratory factors (moderate to
severe dyspnea, exacerbation frequency, and presence
of chronic bronchitis symptoms) were also associated
with worse HRQL. We found an interaction between
age and dyspnea severity (P < .001), which we included
in the models. The linear models with age-by-dyspnea
interaction also show that the impact of dyspnea
was significant for all ages (for the whole population:
b, 22.8; 95% CI, 21.8-23.9) but was more pronounced
in the middle-aged adults. Thus, severe dyspnea was
responsible for 24.6 points in the SGRQ total score
in middle-aged adults, vs 21.0 points in older adults
(Table 2), with a mean score difference of 4.4 points
(95% CI, 5.5 to 3.2), which exceeds the minimum
clinically important difference of 4 units on the SGRQ.
Visual representation of the effect of dyspnea by
age group (Fig 2) confirmed that HRQL differed by
dyspnea severity at any age but also showed that the
impact (difference in SGRQ total score) was more
severe among the middle-aged adults.
These findings were supported by similar associations
in the SPIROMICS cohort. Linear models of HRQL
testing the age group relations with SGRQ total score
(Table 3) confirmed that being older was independently
associated with better HRQL (lower SGRQ total930 Original Researchscore; difference of 4.2 points; 95% CI, 5.7 to
2.6). There was also an age-by-dyspnea interaction
(P ¼ .04), with the impact of dyspnea being higher
in the middle-aged (16.9 points in SGRQ total
score) than in the older (13.9 points) adults (Table 3,
Fig 3).
We attempted to identify alternate explanations for
the differences in HRQL and the disparate impact
of dyspnea by age in a post hoc analysis by using
interaction analyses and evaluation of potential
pathways. For example, several somatic and emotional
factors have been associated with dyspnea, including
age, respiratory symptoms, exacerbation history, anxiety,
and depression.10,14-17 We tested the following
interactions in both cohorts: age-by-chronic bronchitis,
age-by-exacerbation frequency, and dyspnea-by-asthma.
In the COPDGene study, we also tested an age-by-time
interaction with a COPD diagnosis. For this purpose,
we used the answer to the question about participants’
time with COPD diagnosis (categorized as < 10 years
vs $ 10 years, with those with no prior diagnosis or
without a valid response considered as having had
COPD diagnosed for < 10 years). We also tested
interactions among age, dyspnea, and self-reported
physician-diagnosed anxiety or depression among
participants in SPIROMICS (these variables were not
collected at entry to the COPDGene study). With the
exception of an interaction between age and history
of frequent exacerbations among participants in
SPIROMICS, but not in the COPDGene study, none
of these analyses (e-Table 1) indicated alternative
explanations.[ 1 4 9 # 4 CHES T A P R I L 2 0 1 6 ]
TABLE 2 ] Linear Models of SGRQ Total Score Among
Participants With COPD in the COPDGene
Study, Ages 50 to 80 Years (n ¼ 4,097)
Variable b (95% CI)
Age,a y
< 65 Reference
$ 65 3.0 (3.9 to 2.0)
Interaction age  dyspneab
Effect of severe dyspnea
if age < 65 y
24.6 (23.2-25.9)
Effect of severe dyspnea
if age $ 65 y
21.0 (19.6-22.3)
Mean score difference by age
when dyspnea is severe
4.4 (5.5 to 3.2)
Demographic factors
Sex
Male Reference
Female 0.3 (1.2 to 0.6)
Race
Non-Hispanic white Reference
African American 3.0 (1.9-4.1)
Smoking status
Past smoker Reference
Current smoker 2.3 (1.3-3.2)
BMI
< 30 Reference
$ 30 2.2 (1.2-3.2)
Respiratory factors
mMRC dyspnea scorec
< 2 Reference
$ 2 22.8 (21.8-23.9)
Chronic bronchitis
No Reference
Yes 9.6 (8.5-10.6)
Frequent exacerbations
No (< 2/y) Reference
Yes ($ 2/y) 6.8 (5.6-8.0)
Models additionally were adjusted for FEV1 % predicted, time with a COPD
diagnosis, and comorbidities. COPDGene ¼ Genetic Epidemiology of
COPD; mMRC ¼ modified Medical Research Council; SGRQ ¼ St. George’s
Respiratory Questionnaire.
aEffect of age unweighted average over both levels of dyspnea.
bP < .001.
cEffect of severe dyspnea unweighted average over both groups of age.
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Figure 2 – Average effect of different degrees of dyspnea on SGRQ
total score by age group among participants in the Genetic Epidemiology
of COPD study. mMRC ¼ modified Medical Research Council. See
Figure 1 legend for expansion of other abbreviation.We tested whether the findings regarding the SGRQ
total score were maintained for SGRQ subscales. For
all SGRQ subscales in both cohorts, there was a
consistent association between age and subscale score.
The age-dyspnea interactions showing a greater
impact of dyspnea in middle-aged participants were
also present for all subscales in the COPDGene studyjournal.publications.chestnet.organd for SGRQ impact in both cohorts (e-Table 2).
Additional analysis restricted to those with a GOLD
grade of airflow limitation of 1 to 2 confirmed that
the age-related differences in the impact of dyspnea
are present, in both cohorts, even with mild to moderate
obstruction (e-Table 3). Moreover, these results were
maintained when we used the full spectrum of mMRC
values (e-Fig 1) and also when an alternative cut point
of dyspnea severity (mMRC, 0-2 vs 3-4) was tested
in participants in the COPDGene study (e-Table 4,
e-Fig 2).
Lastly, we tested the specific contribution of dyspnea
to explain the differences in SGRQ total score by age
group. We used a strategy based on examining the
change in odds ratio of the exposure variable (age group)
after the inclusion of other variables or sets of variables.
A change in the odds toward the null hypothesis
suggests a mediating effect of the variable being
tested.18,19 We examined not just dyspnea, but all the
variables tested as interaction terms in the main analyses
for their contribution (potential mediation effect) to
the HRQL-age association, in adjusted logistic models
using as outcome the higher tertile of SGRQ total
score (worse HRQL). In participants in the COPDGene
study, a base model without dyspnea showed reduced
odds of reporting low HRQL as age increases (odds
ratio, 0.58), and its value changed in the direction of
the null hypothesis after inclusion of dyspnea (with a
new odds ratio of 0.62, representing a 9.5% contribution
of dyspnea to reducing the differences between age
groups). In similar models using SPIROMICS data,
dyspnea changed the odds of reporting poor HRQL
by 11.3% (base model without dyspnea odds ratio of931
TABLE 3 ] Linear Models of SGRQ Total Score Among
Participants With COPD in SPIROMICS, Ages
50 to 80 Years (n ¼ 1,522)
Variable b (95% CI)
Age,a y
< 65 Reference
$ 65 4.2 (5.7 to 2.6)
Interaction age  dyspneab
Effect of severe dyspnea if
age < 65 y
16.9 (14.6-19.2)
Effect of severe dyspnea if
age $ 65 y
13.9 (11.7-16.0)
Mean score difference by age
when dyspnea is severe
6.2 (8.7 to 3.7)
Demographic factors
Sex
Male Reference
Female 1.5 (0.0-3.0)
Race
Non-Hispanic white Reference
African American 1.7 (0.5 to 3.8)
Smoking status
Past smoker Reference
Current smoker 3.4 (1.8-5.0)
BMI
< 30 Reference
$ 30 3.5 (1.9-5.0)
Respiratory factors
mMRC dyspnea scorec
< 2 Reference
$ 2 15.3 (13.6-16.9)
Chronic bronchitis
No Reference
Yes 6.1 (4.4-7.9)
Frequent exacerbations
No (< 2/y) Reference
Yes ($ 2/y) 6.3 (4.2-8.4)
Models additionally were adjusted for FEV1 % predicted and comorbidities.
mMRC ¼ modified Medical Research Council; SGRQ ¼ St. George’s Res-
piratory Questionnaire; SPIROMICS ¼ Subpopulations and Intermediate
Outcome Measures in COPD Study.
aEffect of age unweighted average over both levels of dyspnea.
bP ¼ .04.
cEffect of severe dyspnea unweighted average over both groups of age.
30
Middle-Aged Adult
40
50
35
45
55
Older Adult
Age Group
Impact of dyspnea severity on SGRQ total score, by age
mMRC 0-1 mMRC 2-4
Figure 3 – Average effect of different degrees of dyspnea on SGRQ
total score by age group among participants in the Subpopulations
and Intermediate Outcome Measures in COPD Study. See Figure 1
and 2 legends for expansion of abbreviations.0.47 vs 0.53 with inclusion of dyspnea). No other
variable tested, in either cohort, had a contribution
of this magnitude. A detailed description of the
contribution of each variable to changing the older
age odds of reporting poor HRQL is presented in
e-Table 5.932 Original ResearchDiscussion
Our investigation of middle-aged vs older
Americans with COPD (1) confirms that younger
age is independently associated with worse HRQL,
(2) provides evidence that the same level of dyspnea
has greater impact on HRQL among middle-aged
adults, and (3) indicates that this age-related disparity
in impact of dyspnea is the main contributor to the
differences in HRQL identified between the two
age-defined groups. The greater impact of dyspnea
in middle-aged subjects was not explained by other
factors usually linked to breathlessness (sex, presence
of asthma, anxiety, depression), by differences in the
distribution of comorbidities or disease phenotypes
(chronic bronchitis, frequent exacerbations), or by
differences in walk distance. This pattern of differences
was robust and was maintained when similar analyses
were applied to participants in a large independent
cohort.
Our analyses indicated that younger adults with
COPD consistently score worse in different HRQL
instruments. This finding is in agreement with findings
from studies of the general population and persons
with other chronic diseases, including fibromyalgia,20
gastroesophageal reflux,21 HIV infection,22 and breast
cancer.23 Using data from patients with chronic lung
diseases (advanced COPD and interstitial lung diseases),
Berry et al.3 recently found that older adults had
lower odds of reporting health-related limitations.
Our investigation, restricting the population to COPD,
confirmed a similar pattern of differences. Importantly,
these results were maintained in analyses additionally
adjusted for the presence of other factors associated with[ 1 4 9 # 4 CHES T A P R I L 2 0 1 6 ]
HRQL, including comorbidities, exacerbation history,
and chronic bronchitis symptoms. The apparent
dissociation between the level of dyspnea and the
patient’s perception of disease severity was reported
by investigators from the Confronting COPD
International Survey24; we extended their findings
with an evaluation of age-related differences in the
impact of dyspnea on HRQL.
Although describing the presence of age-related
differences in HRQL is interesting, it is even more
important to find an explanation for the differences,
as they could have implications for the design of
rehabilitation programs and the selection of age-specific
outcomes for COPD interventions. The reasons for
worse perceived HRQL among younger participants
are still subject to debate and speculation and have
been subject to limited testing. We tested potential
explanations of this phenomenon.
One proposed explanation is that older adults feel
less impact of dyspnea as a result of tolerance and
adaptation after a longer time with the disease.25 To test
that possibility, we examined models and interactions
including time with a diagnosis of COPD (in clinical
terms always unknown) and frequency of chronic
bronchitis and exacerbations. To evaluate whether
the differences resulted from compensatory attempts
by the elderly to avoid triggering dyspnea via lower
activity levels,26,27 we compared distance walked, an
imperfect but useful surrogate of physical activity.
Additional models including total lung capacity did
not change the associations. To test whether less
impact of dyspnea results from the competing effect
of comorbidities more prevalent in the elderly,28 we
included cardiovascular and musculoskeletal diseases
in our models. Conversely, to test whether higher impact
of dyspnea among middle-aged participants could be
due to greater frequency of emotional factors, we also
included in the models and tested interactions with
anxiety and depression.15,29 None of those pathways
changed the differential impact of dyspnea, and the
results were maintained when analyses were restricted
to early disease (spirometry grade, 1-2). However, two
explanations could not be tested in our participants.
First, differences in perception of dyspnea and
ventilatory loads, associated in some but not all studies
with increased age,30,31 could explain a lower impact
of the same level of dyspnea in the elderly. Second,
it is possible that personality changes, changing
expectations, and adaptations with aging result in
a more optimistic overall view about HRQL.32journal.publications.chestnet.orgSome strengths of our analysis include the use of
detailed clinical information from participants in
two large cohorts and our analytic approach, testing
not just for differences but also for factors contributing
to them. In fact, using two different cohorts in
separate analyses allowed us to find a similar profile
of associations, even when the absolute differences
in HRQL scores by age group were not the same.
Nevertheless, this is a cross-sectional analysis, a
study design with limited capacity to evaluate causal
pathways. Other potential limitations include the
use of self-reported dyspnea and the inability to
develop other physiological evaluations of ventilatory
load; however, this is an accepted standard in the
evaluation of HRQL, which is a description of a
unique individual experience with disease.33
Our categorization of dyspnea severity was selected
to match GOLD recommendations on how to judge
symptom burden in COPD (mMRC, 0-1 vs 2-4);
however, we also used COPDGene data to test the
impact of the full spectrum of mMRC values
(e-Fig 1), as well as a higher cut point of dyspnea
severity (mMRC, 0-2 vs 3-4), and the results were
maintained in those new analyses (e-Table 4,
e-Fig 2). Our definition of age groups can be seen as
a potential limitation, as it is in some way arbitrary,
and other authors could group participants in different
ways.34,35 We selected as cut point age $ 65 years
because it is close to retirement age and could have
future public health implications; the lower boundary
of 50 years of age was selected to facilitate clinical
interpretation.
Socioeconomic disparities are also a factor associated
with HRQL in chronic lung disease, particularly
among minorities.36 In agreement with that possibility,
we tested the impact of race and showed that being
of African American race was associated with worse
HRQL. It is still possible that there is an additional
impact of income and other markers of socioeconomic
disadvantages not tested in our models. It is also
possible that better HRQL among older participants
is a survivor effect, which cannot be tested in a
cross-sectional study. We attempted to control in our
models for time with diagnosis, an imperfect surrogate
of disease duration. Finally, a response shift is also
possible but needs to be tested in further longitudinal
analyses.37 Discovering factors related to HRQL is of
greater than theoretical interest because it can help
to identify new targets for clinical interventions, a
crucial goal in chronic and progressive conditions933
such as COPD. Our results, that even with the
described limitations we consider robust, suggest that
strategies to counteract dyspnea, relevant at any age,
could be especially important for younger persons
with COPD.
In conclusion, we demonstrated that older subjects
with COPD report better HRQL than do their younger934 Original Researchcounterparts and that this age-related difference
involves less impact of dyspnea with increased age.
Although dyspnea is important at any age, for the
same level of dyspnea, the decrement in HRQL is
more profound among younger persons with
COPD. Strategies to improve HRQL should
consider the diverse impact of different factors
across age groups.Acknowledgments
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